Agency for Medicinal Products and Medical Devices of the Republic of Slovenia
The joint HMA-EMA Network Data Steering Group (NDSG) is running an EU survey to inform research priorities for AI use in the development and evaluation of medicines. To access the […]
AI research priorities survey Read More »
The Heads of Medicines Agencies (HMA) and the European Medicines Agency (EMA) will host a multi-stakeholder workshop on artificial intelligence (AI) on 20 and 21 November 2025. The workshop has
HMA / EMA multi-stakeholder workshop on artificial intelligence in medicines Read More »
The Accelerating Clinical Trials (ACT EU) initiative aims to identify gaps, issues and bottlenecks (regulatory, resourcing, operational) that prevent non-commercial sponsors from setting up and conducting clinical trials and multinational
EU strengthens support for non-commercial sponsors of clinical trials Read More »
The Accelerating Clinical Trials in the EU (ACT EU) initiative will hold its annual Multi-Stakeholder Platform meeting on 29 October 2025. The event, organised by EMA, will gather regulators, academia,
Upcoming ACT EU Multi-Stakeholder Platform Annual Meeting Read More »
In relation to Commission Implementing Regulation (EU) 2024/2174 of 2 September 2024 laying down rules for the application of Regulation (EU) 2024/573 of the European Parliament and of the Council
We are pleased to announce the launch of a new version of the Clinical Trials Information System (CTIS) public portal, which will allow earlier and more efficient access to clinical
New version of the Clinical Trials Information System (CTIS) public portal Read More »
JAZMP is ambitious to further actively participate in assessment of marketing authorisation applications. In order to strengthen Slovenia’s position in the regulatory EU environment, one of the strategic objectives of
JAZMP AVAILABLE TO ACT AS REFERENCE MEMBER STATE (RMS) IN MRP AND DCP PROCEDURES Read More »
